In Veritas Medical Diagnostics, Inc. (IVMED) Stock

About In Veritas Medical Diagnostics, Inc.

In Veritas Medical Diagnostics, Inc. operates as a development-stage firm, dedicated to researching and developing medical devices designed for near-patient or point-of-care diagnostic applications. The company's flagship product is a prothrombin monitor, crucial for evaluating blood clotting in patients vulnerable to cardiovascular events and cerebrovascular accidents. Beyond this, In Veritas Medical Diagnostics is actively developing a suite of other innovative products. These include a consumer-oriented device to predict labor onset for maternity planning; a comprehensive biomarker monitor that measures key indicators for conditions such as heart attack, HIV, cholesterol levels, and cancer; a non-invasive, continuous blood glucose concentration measurement device; a digital scanning machine offering a non-invasive alternative to traditional 2D X-ray imaging; an osteoporosis detection and monitoring device providing instant bone mineral density readings for affected patients; and a portable digital strip reader for immunoassay applications. The company, incorporated in Inverness, United Kingdom, adopted its current name, In Veritas Medical Diagnostics, Inc., in 2005, evolving from its previous identity as In Vivo Medical Diagnostics, Inc.

In Veritas Medical Diagnostics, Inc. (IVMED) stock trades at $0.00 with a market capitalization of $120. The stock is valued at a price-to-earnings (P/E) ratio of -0.54, price-to-book of -0.01, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.30, and currently trades 100.0% below its 52-week high.

On profitability, In Veritas Medical Diagnostics, Inc. generates a return on equity (ROE) of 1.86%, return on capital employed of 1.70%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.whitebeard.ai